Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Tay

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|December 6, 2023
Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)Daniel Levin, Ellen Lewis, Sylvia McCulloch, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2008
Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myelomaLaura Labonté, Tariq Iqbal, Mukarram A Zaidi, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic ReviewJessie Luo, Nizar J Bahlis, Denise Chan, et al.
Canadian Journal of Kidney Health and Disease|February 24, 2025
Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 YearsChunpeng Nie, Holly Lee, Kim Cheema, et al.
Leukemia & Lymphoma|August 26, 2021
Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemicTom Dunne, Douglas Stewart, Holly Lee, et al.
Clinical Transplantation|June 5, 2019
Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis - Part II: Non-kidney transplantSamuel Bourassa-Blanchette, Vishesh Patel, Greg A Knoll, et al.
Transfusion Medicine Reviews|May 12, 2016
Acquired Factor XIII Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case SeriesKira J Tone, Tyler E James, Dean A Fergusson, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2020
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival OutcomesCarolina Diaz-Pallares, Holly Lee, Joanne Luider, et al.
Cancer Medicine|October 4, 2015
Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature reviewTurki Abdulaziz Alwasaidi, Abdulaziz Hamadah, Sultan Altouri, et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion|September 8, 2021
Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian CenterVictor H Jimenez-Zepeda, Patrick Yau, Douglas Stewart, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|December 6, 2023
Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)Daniel Levin, Ellen Lewis, Sylvia McCulloch, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2008
Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myelomaLaura Labonté, Tariq Iqbal, Mukarram A Zaidi, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic ReviewJessie Luo, Nizar J Bahlis, Denise Chan, et al.
Canadian Journal of Kidney Health and Disease|February 24, 2025
Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 YearsChunpeng Nie, Holly Lee, Kim Cheema, et al.
Leukemia & Lymphoma|August 26, 2021
Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemicTom Dunne, Douglas Stewart, Holly Lee, et al.
Clinical Transplantation|June 5, 2019
Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis - Part II: Non-kidney transplantSamuel Bourassa-Blanchette, Vishesh Patel, Greg A Knoll, et al.
Transfusion Medicine Reviews|May 12, 2016
Acquired Factor XIII Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case SeriesKira J Tone, Tyler E James, Dean A Fergusson, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2020
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival OutcomesCarolina Diaz-Pallares, Holly Lee, Joanne Luider, et al.
Cancer Medicine|October 4, 2015
Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature reviewTurki Abdulaziz Alwasaidi, Abdulaziz Hamadah, Sultan Altouri, et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion|September 8, 2021
Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian CenterVictor H Jimenez-Zepeda, Patrick Yau, Douglas Stewart, et al.
Pageof 9